What is Monte Rosa Therapeutics, Inc.'s debt issuance costs?

Monte Rosa Therapeutics, Inc. (GLUE) reported debt issuance costs of $357K in Q4 2025.

How has Monte Rosa Therapeutics, Inc.'s debt issuance costs changed year-over-year?

Monte Rosa Therapeutics, Inc.'s debt issuance costs increased by 122.8% year-over-year, from $160.25K to $357K.

What does debt issuance costs mean?

Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.

Monte Rosa Therapeutics, Inc. GLUE Debt Issuance Costs

Debt Issuance Costs at other companies

Kymera TherapeuticsKYMR

$425K+53.4%

Viridian Therapeutics, Inc.VRDN

$119.5K—

TG TherapeuticsTGTX

$2.6M—

Other financials

Income statement

See full

Revenue$4.2M-95.0%

Operating income-$50.0M-214%

Net income-$44.5M-195%

EPS (diluted)-$0.45-179%

Balance sheet

See full

Cash & equivalents$159.9M+104%

Total debt$39.1M-6.7%

Total equity$521.9M+89.7%

Total assets$736.4M+87.3%

Cash flow

See full

Operating cash flow-$37.4M+17.9%

CapEx$1.9M+17.7%

Free cash flow-$39.2M+16.7%

Valuation

See full

Market cap$1.76B+361%

Enterprise value$1.64B+381%

P/S41×+38.6×

Profitability

See full

Operating margin-345.2%—

Net margin-302.6%—

FCF margin-45.8%-64.9pp

Returns & leverage

See full

Return on equity-32.6%—

Debt / equity0.1×-0.1×

Current ratio9.5×+3.9×

Where this comes from

Reported directly by Monte Rosa Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentOfFinancingAndStockIssuanceCosts.

The official record: Monte Rosa Therapeutics, Inc.’s 10-K, filed March 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monte Rosa Therapeutics, Inc.'s debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Monte Rosa Therapeutics, Inc.'s debt issuance costs?: Monte Rosa Therapeutics, Inc. (GLUE) reported debt issuance costs of $357K in Q4 2025.
How has Monte Rosa Therapeutics, Inc.'s debt issuance costs changed year-over-year?: Monte Rosa Therapeutics, Inc.'s debt issuance costs increased by 122.8% year-over-year, from $160.25K to $357K.
What does debt issuance costs mean?: Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.